Comparative analysis of protein evolution in the genome of pre-epidemic and epidemic Zika virus

Ramaiah, Arunachalam; Dai, Lei; Contreras, Deisy; Sinha, Sanjeev; Sun, Ren; Arumugaswami, Vaithilingaraja

doi:10.1016/j.meegid.2017.03.012

Cited by 23 publications

(26 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Phylogenetic analyses of ZIKV strains isolated from 1947 to 2016 identified two distinct clades (lineages), African and Asian [10]. The causative agent of the current ZIKV epidemic belongs to the Asian lineage, which, while not closely related to the African lineage, shares a common ancestor [10].…”

Section: Isolation and Characterizationmentioning

confidence: 99%

Section: Isolation and Characterizationmentioning

confidence: 99%

“…The causative agent of the current ZIKV epidemic belongs to the Asian lineage, which, while not closely related to the African lineage, shares a common ancestor [10]. Comparisons of the E protein sequences from the two lineages found that the Asian lineage contains insertions in the E protein glycosylation motif which are not present in the African lineage [10]. When the amino acid sequences of the E protein of ZIKV isolates from human (2015/2016 epidemic), monkey (pre-epidemic), and mosquito (pre-epidemic) were compared, a total of sixteen amino acid substitutions were identified, resulting in subtle structural changes [10].…”

Section: Isolation and Characterizationmentioning

confidence: 99%

“…Comparisons of the E protein sequences from the two lineages found that the Asian lineage contains insertions in the E protein glycosylation motif which are not present in the African lineage [10]. When the amino acid sequences of the E protein of ZIKV isolates from human (2015/2016 epidemic), monkey (pre-epidemic), and mosquito (pre-epidemic) were compared, a total of sixteen amino acid substitutions were identified, resulting in subtle structural changes [10]. These changes, although subtle, may impact ZIKV virulence and host tropism [10].…”

Section: Isolation and Characterizationmentioning

confidence: 99%

“…When the amino acid sequences of the E protein of ZIKV isolates from human (2015/2016 epidemic), monkey (pre-epidemic), and mosquito (pre-epidemic) were compared, a total of sixteen amino acid substitutions were identified, resulting in subtle structural changes [10]. These changes, although subtle, may impact ZIKV virulence and host tropism [10]. …”

Section: Isolation and Characterizationmentioning

confidence: 99%

See 4 more Smart Citations

Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics

McArthur

2017

Viruses

View full text Add to dashboard Cite

Zika is a rapidly emerging public health threat. Although clinical infection is frequently mild, significant neurological manifestations have been demonstrated in infants born to Zika virus (ZIKV) infected mothers. Due to the substantial ramifications of intrauterine infection, effective counter-measures are urgently needed. In order to develop effective anti-ZIKV vaccines and therapeutics, improved animal models and a better understanding of immunological correlates of protection against ZIKV are required. This review will summarize what is currently known about ZIKV, the clinical manifestations and epidemiology of Zika as well as, the development of animal models to study ZIKV infection, host immune responses against ZIKV, and the current state of development of vaccines and therapeutics against ZIKV.

show abstract

Section: Isolation and Characterizationmentioning

confidence: 99%

Section: Isolation and Characterizationmentioning

confidence: 99%

Section: Isolation and Characterizationmentioning

confidence: 99%

Section: Isolation and Characterizationmentioning

confidence: 99%

Section: Isolation and Characterizationmentioning

confidence: 99%

See 3 more Smart Citations

Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics

McArthur

2017

Viruses

View full text Add to dashboard Cite

show abstract

Neurological pathophysiology of SARS‐CoV‐2 and pandemic potential RNA viruses: a comparative analysis

et al. 2021

Self Cite

View full text Add to dashboard Cite

SARS‐CoV‐2 has infected hundreds of millions of people with over four million dead, resulting in one of the worst global pandemics in recent history. Neurological symptoms associated with COVID‐19 include anosmia, ageusia, headaches, confusion, delirium, and strokes. These may manifest due to viral entry into the central nervous system (CNS) through the blood–brain barrier (BBB) by means of ill‐defined mechanisms. Here, we summarize the abilities of SARS‐CoV‐2 and other neurotropic RNA viruses, including Zika virus and Nipah virus, to cross the BBB into the CNS, highlighting the role of magnetic resonance imaging (MRI) in assessing presence and severity of brain structural changes in COVID‐19 patients. We present new insight into key mutations in SARS‐CoV‐2 variants B.1.1.7 (P681H) and B.1.617.2 (P681R), which may impact on neuropilin 1 (NRP1) binding and CNS invasion. We postulate that SARS‐CoV‐2 may infect both peripheral cells capable of crossing the BBB and brain endothelial cells to traverse the BBB and spread into the brain. COVID‐19 patients can be followed up with MRI modalities to better understand the long‐term effects of COVID‐19 on the brain.

show abstract

Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics

Hoffman

Chigbu

Crumley

et al. 2020

Advanced Concepts in Human Immunology: Prospects for Disease Control

View full text Add to dashboard Cite

Comparative analysis of protein evolution in the genome of pre-epidemic and epidemic Zika virus

Cited by 23 publications

References 63 publications

Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics

Zika Virus: Recent Advances towards the Development of Vaccines and Therapeutics

Neurological pathophysiology of SARS‐CoV‐2 and pandemic potential RNA viruses: a comparative analysis

Human Acute and Chronic Viruses: Host-Pathogen Interactions and Therapeutics

Contact Info

Product

Resources

About